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Abstract
Screening patients for methicillin-resistant Staphylococcus aureus (MRSA) carriage at hospital admission is widely accepted as an essential
part of MRSA control programmes. It is assumed, although not proven, that rapid reporting of screening results will improve MRSA
control, provided that a clear action plan for positive cases is in place and is being followed. An effective culture screening method is
direct inoculation of pooled nose, throat and perineal swabs on a well-performing MRSA-selective chromogenic agar; presumptive
MRSA colonies can be conﬁrmed rapidly by latex agglutination with antibodies directed against penicillin-binding protein 2a. This method
will usually produce a positive result after 24 h of incubation in >95% of true-positive cases, and will be sufﬁcient for most initial treat-
ment and infection control decisions; full antimicrobial susceptibilities will be available on the next day. Inoculation of selective enrich-
ment broth containing a colorimetric growth indicator is an alternative overnight culture method, but there may be problems with
overgrowth of other organisms, such as enterococci. PCR methods are now available that can produce same-day results, provided that
samples reach the laboratory in time for batch processing, but cultures are required for susceptibility testing. In comparison with cul-
ture-based methods, PCR tests are costly, and some have relatively high false-positivity rates; deﬁnitive evidence of their clinical cost-
effectiveness is lacking. New point-of-care PCR tests are being introduced that are potentially even more rapid but are even more
expensive; studies on the clinical cost-effectiveness of these very rapid tests are awaited.
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Introduction
True community-acquired methicillin-resistant Staphylococcus
aureus (MRSA) infection is now common in the USA [1], but
the great majority of MRSA infections in Europe are associ-
ated with hospital and healthcare contact [2]. Most of the
time, MRSA colonization (which may last for months or
years) precedes infection. Patients may acquire colonization
during one admission (or healthcare contact) and enter hos-
pital as MRSA carriers on subsequent admissions or trans-
fers. Rates of MRSA carriage among patients on admission
varies with geographical location, but in a high-prevalence
area such as the UK, the rate is approximately 6.5% of gen-
eral medical and surgical patients [3,4]. After admission, colo-
nized patients may become endogenously infected with their
own organism or act as the source of further cross-coloniza-
tion of others. In order to reduce the risk of endogenous
infection and hospital transmission, most guidelines for the
prevention and control of MRSA infection recommend the
identiﬁcation of carriers by screening, followed by isolation
and/or attempts at decolonization [5–9]. The rationale, evi-
dence and strategies for MRSA screening and surveillance
are reviewed in this supplement by Tacconelli [10]; this arti-
cle reviews the laboratory methods for MRSA screening.
Rapid Testing, Turn-Around Times, and
Patient Management
It is widely accepted that rapid reporting of MRSA screening
results is important for MRSA control, although the evidence
base for this is limited. However, rapid reporting is of no
value unless there is a rapid and appropriate response. It is
essential that a plan (or care pathway) is in place, detailing
who should be informed and what is to be done when an
MRSA result is reported, and that these actions are imple-
mented immediately. Similarly, there must be efﬁcient
systems for specimen collection and transport, results
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reporting, and weekend and night-time shifts. Many centres
now screen elective surgical patients in pre-admission clinics
a week or two before admission.
The role of MRSA screening has been recently well
reviewed by Dancer [11]. Screening is only part of MRSA
control, and all screening methods may give false-negative
results. Good hygienic practice and standard infection con-
trol procedures should be in place for all patients, whether
or not their MRSA status is known. Patients who are
assessed at admission as being at high risk for MRSA carriage
should be pre-emptively isolated until a negative screen
result is reported. In certain high-risk clinical areas, a local
risk assessment might conclude that patients who have been
previously MRSA-positive should remain in isolation, even if
a new screen is negative.
Assessment of Screening Methods
Screening tests for MRSA can be assessed on the basis of
sensitivity, speciﬁcity (and positive predictive value (PPV) and
negative predictive value (NPV)), turn-around time (time
between taking the specimen and reporting the result), ease
of performance, and cost. Improving any one of these param-
eters usually worsens one or more of the others, so the aim
should be to optimize cost/performance. As these are bio-
logical screening tests, no method is 100% sensitive and spe-
ciﬁc, and there is therefore no reference standard. This,
together with wide variation in detailed methodologies,
makes comparisons among test methods difﬁcult.
Screening Sites and Pooling
MRSA strains colonize various mucosal sites, including the
anterior nares, throat, and rectum, and some areas of the
skin, especially moist sites such as the axillae, groins and
perineum. Wound and skin puncture sites are also often col-
onized. Rates of colonization vary at different sites but,
because the studies are difﬁcult and costly, there is limited
information on this, and ﬁgures vary. Coello et al. [12] per-
formed the largest reported study on multiple-site screening
of 403 MRSA-colonized patients: nasal swabs identiﬁed 79%
of patients colonized at any site; combined swabs from nose
and throat, nose and perineum, and nose, throat and
perineum identiﬁed 86%, 93% and 98%, respectively
(Table 1). Batra et al. [13] more recently reported on 105
intensive-care patients with MRSA, of whom ﬁve were posi-
tive only at wound sites; among the other 100, approxi-
mately two-thirds were detected by pooled nasal, perineal
and axillary swabs, and one-third by rectal and throat swabs.
Multiple-site screening (ideally nose, throat and perineum for
most patients) is thus necessary to achieve an adequate
pickup rate. In order to save time and costs, screening swabs
from these sites are usually pooled and processed simulta-
neously. This further complicates comparisons among
screening methods, because different studies often screen
different sites and do not give results for individual sites.
Agar Culture Tests
The standard method for MRSA screening (and one still used
for comparisons) is culture of screening swabs on agar. Pre-
sumptive S. aureus colonies are identiﬁed by standard micro-
biological tests, and then tested for methicillin resistance by
disk diffusion, the whole process taking at least 2 days and
usually 3–5 days.
More rapid identiﬁcation of MRSA colonies can be
achieved by direct latex agglutination reaction with a mono-
clonal antibody directed against the variant penicillin-binding
protein 2a, responsible for methicillin resistance and encoded
by mecA. Several studies have shown that the latex agglutina-
tion test is accurate, reliable and fast (15–20 min) for
differentiating colonies of MRSA from those of methicillin-
sensitive S. aureus (MSSA) (or conﬁrming them from
selective chromogenic agar) [14–16], and this test is widely
used [17]. The method requires induction, which provides
improved reliability, although cross-reaction with penicillin-
binding protein 2¢ from coagulase-negative staphylococci may
sometimes occur.
The sensitivity of agar culture screens can be increased by
broth pre-enrichment and/or by using non-selective media.
However, sensitivity is usually sacriﬁced for speed, and speci-
ﬁcity is reduced by using selective media such as salt or salt
mannitol agar (to select S. aureus) and antibiotic (to select
for methicillin-resistance). The selective antibiotic is ideally a
b-lactam; initially, methicillin or oxacillin were used, but
these have been replaced by more stable agents such as
TABLE 1. Methicillin-resistant Staphylococcus aureus (MRSA)
screening results from 403 MRSA-positive patients [12]
Screening site MRSA-
positive (no.)
MRSA-
negative (no.)
% MRSA-
positive
Nose 316 87 79
Perineum 154 249 38
Throat 124 279 31
Groin 36 367 16
Axilla 41 362 10
Nose and throat 345 58 86
Nose and perineum 376 27 93
Nose, throat, and perineum 396 7 98
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cefoxitin. The quinolone ciproﬂoxacin was used for a period,
because MRSA strains have been, until recently, usually cip-
roﬂoxacin-resistant, whereas MSSA strains have generally
remained susceptible. However, this differentiation is not
reliable—especially with the emergence of ciproﬂoxacin-sus-
ceptible community MRSA strains—and ciproﬂoxacin should
not now be used for selection [18].
Conventional selective media are now being replaced by
chromogenic agars. These allow rapid, direct microbial iden-
tiﬁcation by incorporating chromogenic substrates for spe-
ciﬁc bacterial enzymes that result in different species
producing different-coloured colonies on culture. S. aureus
can be identiﬁed by a substrate colour change produced by
enzymes such as staphylococcal a-glucosidase; adding a selec-
tive b-lactam to the agar allows rapid identiﬁcation of MRSA.
These agars are generally more speciﬁc and have better PPVs
than traditional b-lactam-containing mannitol salt agar [19],
and colour identiﬁcation of MRSA reduces laboratory work
time. Results are usually available after 18–24 h of culture,
although sensitivity is often improved at 48 h.
A wide range of commercial chromogenic agars is available
for MRSA detection by direct inoculation of screening swabs.
These have been reviewed recently by Malhotra-Kumar et al.
[20], who also provide information on agar composition and
a full summary and discussion of performance; readers are
referred to their paper for details. Reported sensitivities and
speciﬁcities vary both among and within studies, and are difﬁ-
cult to summarize, because reference standards, culture
sites, pooling, incubation times, and inoculum size vary.
Nevertheless, as would be expected, there is a tendency
towards high (>95–100%) speciﬁcity with direct inoculation
at 16–18 h of incubation, which decreases somewhat after
24–48 h, and variable sensitivity (c. 50–70%) at 16–18 h,
which increases to 80–100% after 24–48 h. Reported times
from inoculation of agar to conﬁrmation of MRSA range
from approximately 1.5 to 3 days, with an average of
approximately 2 days.
To obtain the best balance between speed and sensitivity,
Malhotra-Kumar et al. [20] favour direct inoculation onto
chromogenic agar (they use ‘MRSA Select’), (Bio-Rad Labora-
tories, Nazarethe Eke, Belgium), followed by overnight
enrichment culture to improve sensitivity, but at the cost of
additional processing time. However, they note that Hansen
et al. (46th ICAAC, 2006, Abstract 2719) found Chromo-
genic MRSA/Denim Blue Agar (Oxoid, Basingstoke, UK) to
have a sensitivity of 90% and speciﬁcity of 96% with direct
plating after 24 h of incubation. We (unpublished data) found
a similar sensitivity of 95% after 24 h, and the denim blue
colonies of MRSA on this agar are also easy to identify. In
our laboratory, therefore, we routinely use Oxoid Chromo-
genic MRSA agar with direct inoculation and 24 h of incuba-
tion. This method is simple and relatively inexpensive, and
for the majority of patients provides a reliable culture result
on the day after swabbing.
Broth Culture Tests
Culture of MRSA screening swabs in selective broth can
increase the sensitivity of the test, provided that the selec-
tive medium is not inhibitory to the MRSA strain involved. A
variety of chemical and antibiotic ingredients have been used
to favour MRSA while inhibiting other organisms. By adding
an indicator of bacterial growth, these broths can produce a
deﬁnitive negative result overnight, with possible positives
being conﬁrmed by further tests and cultures [21]. Kelly
et al. [22], demonstrated that swabs can be agitated in the
selective broth on the ward and then discarded, the broths
being sent to the laboratory, with savings in time and labora-
tory labour. The original broths contained ciproﬂoxacin to
select for MRSA, but this should now be replaced by cefoxi-
tin because of the increasing incidence of ciproﬂoxacin-sus-
ceptible MRSA. A problem with these broths is that a
proportion of tests produce an intermediate colour change
after overnight incubation, often due to overgrowth with
enterococci that may not be inhibited by the MRSA selective
agents. Cultures may therefore have to be prolonged, and
suspected positives subcultured on chromogenic or other
selective MRSA agar for conﬁrmation.
Nucleic Acid Ampliﬁcation Tests
Methicillin resistance is encoded by the mecA gene, which is
associated with a mobile element designated staphylococcal
chromosome cassette mec (SCCmec) [23]. There are several
types of SSCmec in different MRSA clonal lineages, and new
types are continuously appearing. A range of rapid PCR
screening tests for MRSA have been developed, based on
simultaneous ampliﬁcation and detection of mecA and genes
characteristic of S. aureus. However, methicillin-resistant
coagulase-negative staphylococci (MRCNS) also possess
mecA, and dual colonization with methicillin-resistant coagu-
lase-negative staphylococci and MSSA is not infrequent: for
example, this occurred in 3.4% of cardiothoracic patients
studied in Germany [24]. PCR systems that use unlinked
primers targeting an S. aureus species-speciﬁc gene and mecA,
such as the LightCycler Staphylococcus and MRSA detection
kit (LC Assay; Roche Diagnostics, Mannheim, Germany) and
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the Hyplex StaphyloResist PCR (BAG, Lich, Germany), may
give false-positive results with such mixtures [20].
To resolve this problem, the BD GenOhm system (previ-
ously known as IDI-MRSA) (BD Diagnostics, San Diego, CA,
USA) ampliﬁes MRSA-speciﬁc sequences by targeting a single
locus that includes the right extremity of SCCmec down-
stream of mecA, and part of the adjacent S. aureus-speciﬁc orfX
gene. Five primers target SCCmec sequences corresponding
to types I, II, III, IVa, IVb, and IVc, and one primer and three
molecular beacons are speciﬁc for orfX [25]. The test is per-
formed in real time with ﬂuorescence detection. Similar assays
are the GeneXpert MRSA (Cepheid, Sunnyvale, CA, USA)
[26] and the GenoType MRSA Direct (Hain Lifescience, Neh-
ren, Germany), the latter using hybridization to oligonucleo-
tides on a cellulose strip for detection and identiﬁcation. In
contrast, qMRSA [27] is an in-house triplex quantitative PCR
assay that ampliﬁes mecA and femA from S. aureus and Staphy-
lococcus epidermidis to identify the origin of the mecA signal.
Molecular methods can give false-positive results if non-
speciﬁc sequences are ampliﬁed. Rupp et al. [28] pointed out
that single-locus PCR methods for MRSA, such as the IDI/
GenOhm and Hain tests, are potentially especially susceptible
to this problem, and described an MSSA isolate containing
only small fragments of the right extremity of SCCmec that
resulted in false-positive reactions in the Hain test. Desjar-
dins et al. [29] used the IDI-MRSA test to examine nasal and
rectal swabs pooled in a selective broth. Of 298 IDI-MRSA
assay-positive broths, 103 could not be conﬁrmed by culture;
MSSA was recovered from 77 of these 103, and gave positive
results with IDI-MRSA. There were 17 different pulsed-ﬁeld
gel electrophoresis genotypes among these MSSA strains,
and approximately half of them were similar to common
local MRSA genotypes, including the community-acquired
MRSA clones USA100 and USA500, which may have been
MSSA strains that had not yet acquired mecA. Alternatively,
MRSA strains may lose mecA and become methicillin-suscep-
tible but still retain partial SCCmec elements that react with
the primers [20,25]. Furthermore, because these systems
target SSCmec elements, they may give false-negative results
if—as is increasingly the case—local strains of MRSA appear
to be of unusual or variant SSCmec types [30,31]. Francois
et al. [30] found the IDI-MRSA and Hain systems to have
poor speciﬁcity when tested against 93 MRSA and 89 MSSA
strains of diverse genetic backgrounds. Their own multilocus
quantitative PCR system was not affected by this problem,
and they warn that users of orfX–SSCmec-based assays
should repeatedly monitor local epidemiology to minimize
the risks of failing to detect emerging MRSA clones. A ﬁnal
problem is that topical or systemic antimicrobial therapy may
kill MRSA but their DNA may remain, yeilding false-positive
results. Further investigations on the accuracy of PCR
screening tests after nasal decolonization are required.
The IDI/GenOhm system is designed—and licensed by the
FDA—for use with nasal swabs only. Numerous studies of
this system in comparison with culture have shown sensitivi-
ties, speciﬁcities, NPVs and PPVs for nasal swabs of c. 88–
95%, 92–99%, 97–99%, and 83–84%, respectively [3,32–35].
Taking into account the fact that 90–95% of swabs will be
true negatives, the high NPV is to be expected, and the low
PPV may be a reﬂection of a relatively high rate of false posi-
tivity. However, as discussed previously, interpretation of
these ﬁgures is complicated by the lack of a valid standard
method for comparison. Samples from non-nasal sites and
from multiple-site pooled swabs generally give similar results
[3,32–34], although a recent study showed that screening
with nasal swabs alone would have failed to identify 24% of
MRSA-colonized patients [36].
The processing time for these PCR tests is c. 1.5–2 h, but the
total turn-around time from sampling to reporting is much
longer. Although many publications have reported extremely
rapid turn-arounds, in the order of 4 h, we [3] (unpublished
results) found a mean turn-around time for the IDI-MRSA test
in routine use in a London hospital located on two sites to be
22 h; because the laboratory processing took place during day-
time hours only, much of this delay was due to specimens sent
at night and weekends missing batch processing runs, although
some was due to slowness of transportation. Similar lengthy
turn-around times for laboratory-based PCR tests have been
reported by others [37,38]. Some workers have used a broth
enrichment step to improve the sensitivity of pooled nasal and
rectal swabs at the expense of further turn-around delay [29].
A Scottish systematic review of MRSA screening [39] con-
cluded that ‘in routine clinical practice, where samples require
to be batched before testing, PCR does not have a turnaround
time advantage over chromogenic agar testing.’ Many screening
swabs can give a same-day result when processed by present
PCR systems, but users should be aware that in routine practice
a signiﬁcant proportion will give a result on the day after sam-
pling. Furthermore, good clinical microbiological and infection
control practice requires that positive cases will then need cul-
ture (or re-swabbing and reculture) to conﬁrm antimicrobial
susceptibilities, and other tests for treatment and epidemiologi-
cal reasons, as well as MRSA conﬁrmation.
However, PCR screening systems are becoming available
that can be used by clinical staff and allow PCR testing 24 h
a day at the bedside or point of care (‘GeneXpert’;
Cepheid). If these are shown to be practical and effective,
turn-around times will become much closer to the process-
ing time of c. 2 h. Independent assessments of point-of-care
PCR screening are awaited.
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The costs of PCR tests for MRSA screening are signiﬁcantly
higher than for conventional culture. It is difﬁcult to deﬁne
the exact costs, because reagent and equipment costs differ
with rental packages, quantity discounts, and currency rates.
However, the Scottish systematic review referred to previ-
ously [39] calculated that the cost of a screening test per-
formed with chromogenic agar, latex agglutination and a
conﬁrmatory disk test was £4.35 for a negative test and £7.45
for a positive test, and the cost of the IDI-MRSA real-time
PCR test was £19.40 for both positive and negative speci-
mens. We calculated that reagent costs alone were £10 for
the PCR test, as compared with less than £2 for conventional
tests [3]. The costs for point-of-care PCR screening such as
the GeneXpert system are even higher, at about £25 per test.
Ritchie et al. [39] concluded that (for the Scottish National
Health Service) ‘the resource costs required for PCR screen-
ing of swabs are high, meaning that the technology is unlikely
to represent a realistic replacement for culture methods’.
Staff costs may be lower than with conventional tests because
‘hands-on’ time with automated systems may be shorter;
however, costs will increase if rapid testing is to be available
24 h a day. We believe that, for appropriate therapy and epi-
demiological control, positive screens should also have an
MRSA culture and antimicrobial susceptibility test; these costs
should be factored into business plans for rapid PCR testing.
A strong argument for replacing conventional MRSA cul-
ture screening with rapid PCR tests is that the increased
costs can be justiﬁed by improvements in patient care,
resulting in reduced MRSA transmission and infection rates
and consequent reductions in mortality, morbidity, and
healthcare costs. Indeed, it is argued that the savings in
healthcare costs will greatly outweigh the increased costs of
rapid testing. Several papers have been published showing
that MRSA rates have fallen after the introduction of rapid
screening; however, many of these studies have been uncon-
trolled and/or have had relatively small numbers of patients
[3,38,40,41], and it is not known whether MRSA rates would
have fallen for other reasons, even if the rapid tests had not
been introduced. The literature is reviewed in detail by Tac-
conelli [10] in this supplement; she concludes that the evi-
dence for the clinical effectiveness of rapid PCR screening is
inconclusive. Our own large, randomized, cluster-controlled
cross-over study of the impact of the IDI-MRSA rapid
screening test at admission to general medical and surgical
wards where pre-emptive isolation of high-risk patients was
practised showed no reduction in MRSA transmission or
infection rates as compared with conventional culture
screening [3]. Similar ﬁndings have been reported by others
[37,38]. It is also striking that national MRSA bacteraemia
rates in England have fallen by approximately 30% between
2008 and 2009 as a result of an MRSA improvement pro-
gramme that did not include rapid screening [42].
Conclusions
MRSA screening is only effective if systems are in place to
ensure rapid transport of specimens to the laboratory, rapid
reporting of results to responsible clinicians, and rapid action
to ensure isolation/cohorting and decolonization of colonized
patients. For the greatest yield, screening swabs should be
taken from multiple sites; pooling of these swabs will reduce
laboratory work time and costs. Direct plating on a well-per-
forming selective chromogenic agar of pooled nose and throat
swabs (with or without a perineal swab) will usually produce
a positive result after 24 h of incubation in >95% of true-posi-
tive cases. This will be a sufﬁcient basis for most initial treat-
ment and infection control decisions, and appears to be
better than—or at least as good as—enrichment culture sys-
tems. Presumptive MRSA colonies can be conﬁrmed rapidly
by a latex agglutination test, and full antimicrobial susceptibili-
ties will be available on the next day. Rapid PCR methods can
produce same-day results, provided that samples reach the
laboratory in time for batch processing. Commercial systems
are validated only for nasal swabs but appear to be effective
with most multiple-site pooled swabs. However, some PCR
tests may have relatively high false-positive rates (as com-
pared with culture), owing to non-speciﬁc ampliﬁcation,
and local quality assurance systems should be in place to
ensure the continuing reliability of results. Additional cul-
tures of PCR MRSA-positive cases will be required to obtain
antimicrobial susceptibilities and epidemiological characteriza-
tion of the isolates concerned. There is a lack of evidence so
far that these PCR screening tests justify their increased
costs. Even more rapid point-of-care PCR screening tests
are becoming available, and studies on their cost-effectiveness
are awaited.
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